SEC Filing Document

Company: ERock, Inc.
Ticker: 
CIK: 2110029
Filing Type: DRS
Document Type: DRS
Date Filed: 2026-02-17
Accession Number: 0001193125-26-054926
Exchange: 
SIC Code: 3620
SIC Description: Electrical Industrial Apparatus
URL: https://www.sec.gov/Archives/edgar/data/2110029/000119312526054926/filename1.htm

Chunk 62 of 96
Word Count: 1493
Character Count: 9244

Document Content:

of nolo contendere to, any felony or any crime involving Table of Contents moral turpitude, or (vi) his willful failure or refusal, other than due to disability, to perform his obligations or to follow any lawful directive from the Board. If his actions or omissions as set forth in clauses (i), (ii), (iii) or (vi) are curable, then he will receive a 30-day cure period. “Good Reason” for purposes of Mr. Carrington’s employment agreement generally means: (i) a material breach by ER Management of the employment agreement, (ii) a material diminution in his duties, title, authority or responsibilities, or (iii) a material reduction in his base salary (other than any across-the-company reductions affecting substantially all of the senior executives and which reduction does not reduce his base salary by more than 10%). He must provide ER Management a 30-day cure period following written notice of the condition constituting Good Reason.

Prior to his appointment as Chief Executive Officer, ER Holdings and Mr. Carrington were parties to a letter agreement
with respect to his services as a director, pursuant to which he was eligible to receive (i) a biweekly fee of $8,333, (ii) a $475,000 additional cash payment upon the Debt Repayment, which was subsequently reduced to $100,000 pursuant to his
employment agreement as described above, and (iii) 2,323 Compensatory Units, of which 50% vested upon the Debt Repayment and the remaining 50% vests in 12 equal monthly installments commencing on January 9, 2026. Upon his appointment as Chief
Executive Officer, Mr. Carrington also received a grant of 22,715 Compensatory Units, which vests in equal monthly installments over thirty-six months commencing on December 26, 2025, subject to his
continued service with the Company through the applicable vesting dates.

Corey Amthor

ER Management previously entered into an employment agreement in October 2014 with Mr. Amthor upon his initial hire as a
partner. Such agreement provided for Mr. Amthor’s base salary and eligibility to receive a discretionary bonus determined at the sole discretion of ER Management based on individual and overall organization performance.

Ian Blakely

Management entered into an offer letter and employment agreement with Mr. Blakely in January 2015, which provide for his base salary, eligibility to receive a discretionary bonus determined at the sole discretion of ER Management based on
individual and overall organization performance, and eligibility to receive a grant of profits interest units (which were granted as profits interest units in ERock Holdings, Ltd.).

Paul Froutan

Management entered into an offer letter and employment agreement with Mr. Froutan in May 2022, which provide for his base salary, eligibility to receive a discretionary bonus determined at the sole discretion of ER Management based on
individual and overall organization performance, and a grant of Compensatory Units which vests 25% one year after the date of grant and the remaining 75% in equal monthly installments thereafter.

Thomas McAndrew

Management entered into an employment agreement with Mr. McAndrew in June 2025 in connection with his transition to the role of advisor to the Chief Executive Officer, which has an initial term of one year and may be extended by mutual
agreement. Such agreement provides for (i) an initial annual base salary of $200,000 that increased to $275,000 upon the Debt Repayment, (ii) a cash incentive equal to $75,000 multiplied by the product of (a) 1.5 and (b) a fraction
the numerator of which is the number of months that elapsed between the date of the agreement and the Debt Repayment date and the denominator of which is 12 (the “Debt Repayment Success Fee”), and (iii) eligibility to receive
commissions on sales agreements entered into with certain parties, which commissions are reduced by his company-reimbursed expenses, his base salary, the earned Debt

Table of Contents

Repayment Success Fee, commissions payable to any other sales employee, and deals yielding gross margin of less than 20%. Mr. McAndrew’s employment may be terminated for Cause at any
time, without Cause upon 90 days advance written notice, or upon written notice in the event of disability or upon death. If Mr. McAndrew’s employment is terminated without Cause prior to the end of the initial term, he will receive any
earned sales commissions through the end of the 90-day notice period. The agreement also contains non-competition covenants covering the
one-year period post-termination or until his termination date if he is terminated without Cause prior to the end of the initial term, in which case ER Management may elect to extend the non-compete period for one year subject to ER Management’s payment of his base salary through such extension period. ER Management also agreed to pay 100% of the premiums for Mr. McAndrew’s coverage
under ER Management’s health and other insurance plans.

“Cause” for purposes of
Mr. McAndrew’s employment agreement generally means his: (i) willful misconduct which has been, or would reasonably be expected to be, materially injurious to ER Management and its affiliates, (ii) fraud, embezzlement or any
other act of dishonesty against ER Management or its affiliates, or a willful breach of a fiduciary duty to ER Management or its affiliates, (iii) conviction of, or plea of guilty or nolo contendere to a felony or any crime involving moral
turpitude, (iv) material breach of any agreement with or policy of ER Management or its affiliates, and such breach is not cured within 30 days of written notice, (v) abuse of any alcoholic, controlled or illegal substance or drug which
materially interferes the performance of his duties, or (vi) commitment of any act that damages the reputation of ER Management or its affiliates.

Outstanding Equity Awards at Fiscal Year-End

The following table presents information regarding the outstanding equity awards held by our NEOs as of December 31, 2025.

Stock Awards

Name Grant Date Number of shares or units of stock that have not vested (#) (1) Market value of shares of units of stock
that have not vested ($) (2)

John Carrington June 18, 2025 968	(3)

November 26, 2025 22,084	(4)

Corey Amthor (5) April 1, 2023 189

July 1, 2024 241

July 29, 2025 3,001

November 26, 2025 7,362

Ian Blakely (6) April 1, 2023 189

July 29, 2025 5,000

November 26, 2025 1,227

Paul Froutan (7) May 16, 2022 322

June 1, 2024 824

July 29, 2025 3,001

November 26, 2025 2,454

Thomas McAndrew — — —

(1)	Reflects outstanding unvested Compensatory Units held by the applicable NEO as of December 31, 2025.

(2)	The Compensatory Units are intended to qualify as “profits interests” for U.S. tax purposes.
They do not require the payment of an exercise price but are economically similar to stock appreciation rights because they have no value for tax purposes as of the grant date and will obtain value only as the underlying value of the security rises
above its grant date value, which is referred to as the “Threshold Amount.” The market value as of December 31, 2025 of such unvested Compensatory Units were calculated based on a third-party valuation of ER Holdings and the
applicable Threshold Amount of such Compensatory Units

Table of Contents

(3)	These Compensatory Units will vest in equal monthly installments through November 26, 2026 subject to the
NEO’s continued service through each vesting date.

(4)	These Compensatory Units will vest in equal monthly installments through November 26, 2028, subject to
the NEO’s continued service through each vesting date.

(5)	The Compensatory Units reported for Mr. Amthor will vest as reflected below subject to his continued
service through each vesting date.

Grant Date Vesting Schedule

April 1, 2023 144 units will vest upon this offering, a Company Sale (as defined below), or a Distribution Achievement (as defined below)
and the remaining unvested units will vest monthly at the end of each month through March of 2027.

July 1, 2024 150 units will vest upon this offering, a Company Sale, or a Distribution Achievement and the remaining unvested units will
vest monthly at the end of each month through May of 2028.

July 29, 2025 The unvested units will vest monthly on the monthly anniversary of the grant date through July 29, 2028.

November 26, 2025 The unvested units will vest monthly on the monthly anniversary of the grant date through November 26,

(6)	The Compensatory Units reported for Mr. Blakely will vest as reflected below subject to his continued
service through each vesting date.

Grant Date Vesting Schedule

April 1, 2023 144 units will vest upon this offering, a Company Sale, or a Distribution Achievement and the remaining unvested units will
vest monthly at the end of each month through March of 2027.

July 29, 2025 The unvested units will vest monthly on the monthly anniversary of the grant date through July 29, 2028.

November 26, 2025 The unvested units will vest monthly on the monthly anniversary of the grant date through November 26,

(7)	The Compensatory Units reported for Mr. Froutan will vest as reflected below subject to his continued
services through each vesting date.

Grant Date Vesting Schedule